GlassScriptPhysician profile
Tamara Arboleda
NPI 1750915112
$3,635.67
in general payments reported to CMS, 2019-2025
39 companies · $2,241 in 2025
The $2,241 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $54.28 · 2022: $58.57 · 2023: $810 · 2024: $472 · 2025: $2,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,186 · Education: $337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,185.79 |
| Education | $337.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $371.61 | 2023-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Astrazeneca Pharmaceuticals LP | $318.17 | 2022-2025 | Calquence, Tagrisso, Enhertu |
| Astellas Pharma US INC | $274.96 | 2022-2025 | Cresemba, Xospata, Vyloy |
| Incyte Corporation | $244.05 | 2021-2025 | Jakafi, Niktimvo |
| Sobi, INC | $188.05 | 2024-2025 | |
| Lilly USA, LLC | $168.23 | 2023-2024 | Jaypirca |
| Beigene USA, INC. | $167.34 | 2023-2024 | Brukinsa |
| Janssen Biotech, INC. | $158.50 | 2021-2025 | Rybrevant, Darzalex, Talvey |
| Glaxosmithkline, LLC. | $145.92 | 2024-2025 | Ojjaara, Blenrep, Jemperli |
| Abbvie INC. | $132.95 | 2021-2025 | |
| Celgene Corporation | $126.36 | 2022-2025 | Reblozyl |
| Novartis Pharmaceuticals Corporation | $109.71 | 2025 | |
| Eisai INC. | $109.43 | 2025 | |
| Syndax Pharmaceuticals, INC. | $90.45 | 2025 | |
| Daiichi Sankyo INC. | $84.84 | 2024-2025 | Vanflyta, Datroway |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Arboleda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.